Jun Zhang1, Wei Cao, Qin Xu, Wan-tao Chen. 1. Department of Oral and Maxillofacial Surgery, Shanghai Key Laboratory of Stomatology, Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, PR China.
Abstract
AIMS: To investigate the expression of EMP1 in oral squamous cell carcinoma (OSCC) tissues and its correlation with available clinical parameters of patients with OSCC. METHODS: The mRNA levels of EMP1 were measured in 18 paired OSCC and corresponding adjacent normal tissues using RT-PCR. Another 45 pairs of OSCC samples were selected to detect the mRNA level of EMP1 using quantitative RT-PCR (qRT-PCR). The protein levels of EMP1 were also evaluated in 60 cases of patients with OSCC using immunohistochemical staining. The correlation between EMP1 expression and clinical parameters was analysed with non-parametric analysis. RESULTS: The results of RT-PCR and qRT-PCR showed that, compared with the paired normal tissues, the mRNA levels of EMP1 were significantly decreased in OSCC. The immunohistochemical results indicated that the EMP1 protein was also downregulated in OSCC (p=0.031). Decreased expression of EMP1 was significantly correlated with clinical stage (p=0.002) and lymph node metastasis (p=0.044) of patients with OSCC. Meanwhile, there was a significant difference between OSCCs at early and advanced stages (p=0.003), and between OSCCs with lymph node metastasis and no lymph node metastasis (p=0.045), respectively. CONCLUSIONS: The results suggest that EMP1 may be a tumour suppressor and associated with lymph node metastasis in OSCC.
AIMS: To investigate the expression of EMP1 in oral squamous cell carcinoma (OSCC) tissues and its correlation with available clinical parameters of patients with OSCC. METHODS: The mRNA levels of EMP1 were measured in 18 paired OSCC and corresponding adjacent normal tissues using RT-PCR. Another 45 pairs of OSCC samples were selected to detect the mRNA level of EMP1 using quantitative RT-PCR (qRT-PCR). The protein levels of EMP1 were also evaluated in 60 cases of patients with OSCC using immunohistochemical staining. The correlation between EMP1 expression and clinical parameters was analysed with non-parametric analysis. RESULTS: The results of RT-PCR and qRT-PCR showed that, compared with the paired normal tissues, the mRNA levels of EMP1 were significantly decreased in OSCC. The immunohistochemical results indicated that the EMP1 protein was also downregulated in OSCC (p=0.031). Decreased expression of EMP1 was significantly correlated with clinical stage (p=0.002) and lymph node metastasis (p=0.044) of patients with OSCC. Meanwhile, there was a significant difference between OSCCs at early and advanced stages (p=0.003), and between OSCCs with lymph node metastasis and no lymph node metastasis (p=0.045), respectively. CONCLUSIONS: The results suggest that EMP1 may be a tumour suppressor and associated with lymph node metastasis in OSCC.
Authors: Joanne Durgan; Guangbo Tao; Matthew S Walters; Oliver Florey; Anja Schmidt; Vanessa Arbelaez; Neal Rosen; Ronald G Crystal; Alan Hall Journal: EMBO Rep Date: 2014-11-13 Impact factor: 8.807
Authors: Hailey A Clancy; Hong Sun; Lisa Passantino; Thomas Kluz; Alexandra Muñoz; Jiri Zavadil; Max Costa Journal: Metallomics Date: 2012-06-19 Impact factor: 4.526